RNACCartesian Therapeutics, Inc.

RNAC Stock Price, Valuation & Chart | Cartesian Therapeutics, Inc.

Compare

$9.080-0.22 (-2.37%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology RNAC intrinsic value RNAC calculated fair value vs price

Overview Financials Dividends Ratios

RNAC Historical price chart

RNAC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization266.78M

PE Ratio-2.41

EPS-3.76

Trading Volume128.49K

Today's High/Low9.64/8.84

Dividend Yield0.00

52 Week High/Low11.0/5.6

Shares Outstanding29.38M

RNAC Financial Statement

RNAC Analyst ratings

RNAC Analysis & performance metrics

RNAC Company profile

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic…

RNAC Management team

Name

Position

Metin Kurtoglu M.D., Ph.D.

Consultant

Blaine T. DavisCFO

Chief Financial Officer

Milos Miljkovic M.D., Ph.D.

Chief Medical Officer

Chris Jewell Ph.D.

Chief Scientific Officer

Matthew Bartholomae J.D.

General Counsel & Secretary

Carsten Brunn Ph.D.CEO

President, Chief Executive Officer & Director

Emily English Ph.D.COO

Chief Operating Officer

Name

Position

Metin Kurtoglu M.D., Ph.D.

Consultant

Blaine T. DavisCFO

Chief Financial Officer

Milos Miljkovic M.D., Ph.D.

Chief Medical Officer

Chris Jewell Ph.D.

Chief Scientific Officer

Matthew Bartholomae J.D.

General Counsel & Secretary

Carsten Brunn Ph.D.CEO

President, Chief Executive Officer & Director

Emily English Ph.D.COO

Chief Operating Officer

Management Team

Metin Kurtoglu M.D., Ph.D.

Consultant

Blaine T. DavisCFO

Chief Financial Officer

Milos Miljkovic M.D., Ph.D.

Chief Medical Officer

Chris Jewell Ph.D.

Chief Scientific Officer

Matthew Bartholomae J.D.

General Counsel & Secretary

Carsten Brunn Ph.D.CEO

President, Chief Executive Officer & Director

Emily English Ph.D.COO

Chief Operating Officer

Management

Metin Kurtoglu M.D., Ph.D.

Consultant

Blaine T. DavisCFO

Chief Financial Officer

Milos Miljkovic M.D., Ph.D.

Chief Medical Officer

Chris Jewell Ph.D.

Chief Scientific Officer

Matthew Bartholomae J.D.

General Counsel & Secretary

Carsten Brunn Ph.D.CEO

President, Chief Executive Officer & Director

Emily English Ph.D.COO

Chief Operating Officer

Total 7 executives

RNAC Frequently asked questions

What is Cartesian Therapeutics, Inc. (RNAC) Stock Price?

Current stock price of Cartesian Therapeutics, Inc. (RNAC) stock is $9.080. The stock price is -2.37% lower in the session. The intraday range can be seen from this page. Volume of Cartesian Therapeutics, Inc. (RNAC) stock is 128.49K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Cartesian Therapeutics, Inc. (RNAC) stock price going up or down today?

The stock price of Cartesian Therapeutics, Inc. (RNAC) can change with earnings, company news, and overall market sentiment. Cartesian Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Cartesian Therapeutics, Inc. stock expensive at its current price?

Whether Cartesian Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RNAC on this page is -2.41. EPS on this page is -3.76. Compare those figures with peers and growth expectations before deciding if the current Cartesian Therapeutics, Inc. price is justified.

How has the stock price of Cartesian Therapeutics, Inc. (RNAC) performed historically?

Historical performance for Cartesian Therapeutics, Inc. (RNAC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RNAC reacted to past earnings and market events.

Should I buy Cartesian Therapeutics, Inc. (RNAC) stock, at this price?

Buying Cartesian Therapeutics, Inc. (RNAC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.